Sightera Biosciences
It develops a patient-derived AI drug discovery platform intended to help scale data-driven therapeutic discovery.
Overview
Sightera Biosciences builds a patient-derived AI drug discovery platform, applying artificial intelligence to support drug discovery workflows built around patient-derived biology. The company operates in AI healthcare, with relevance for biotechnology and pharmaceutical teams seeking data-driven discovery tools. The Antwerp company raised €3 million in a pre-seed round announced in July 2026 to scale the platform. Its stated differentiator is the combination of patient-derived inputs with AI, positioning it around patient-centered drug discovery rather than generic computational screening.
Funding History
Antwerp’s Sightera Biosciences raises €3 million to scale its patient-derived AI drug discovery platform
Frequently Asked Questions
- How much has Sightera Biosciences raised in total?
- Sightera Biosciences has raised a total of $3M across 1 funding round.
- What does Sightera Biosciences do?
- Sightera Biosciences builds a patient-derived AI drug discovery platform, applying artificial intelligence to support drug discovery workflows built around patient-derived biology. The company operates in AI healthcare, with relevance for biotechnology and pharmaceutical teams seeking data-driven discovery tools. The Antwerp company raised €3 million in a pre-seed round announced in July 2026 to scale the platform. Its stated differentiator is the combination of patient-derived inputs with AI, positioning it around patient-centered drug discovery rather than generic computational screening.
- Where is Sightera Biosciences headquartered?
- Sightera Biosciences is headquartered in Antwerp, Belgium.
Related Insights
A comprehensive analysis of Sage's funding history, investors, competitive position, and growth trajectory in the AI Healthcare space.
A data-driven analysis of AI funding across all 17 sectors — from Foundation Models to AI Healthcare — with sector totals, deal counts, top companies, and investment trends for 2026.
A comprehensive, data-driven analysis of AI venture funding in Q1 2026. $35.9 billion raised across 95 deals, with 15 mega-rounds capturing 85.5% of total capital. Europe breaks out with $6.65B, and billion-dollar seed rounds arrive for the first time.